Chanticleer Holdings just filed a prospectus, suggesting it plans to soon issue some securities

Chanticleer Holdings just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

424B3 1 form424b3.htm   Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-235301       PROPOSED MERGER   YOUR VOTE IS VERY IMPORTANT   To the Stockholders of Chanticleer Holdings, Inc. and Sonnet BioTherapeutics, Inc.:   Chanticleer Holdings, Inc., a Delaware corporation, or Chanticleer, Biosub Inc., a Delaware corporation and a wholly-owned subsidiary of Chanticleer (“Merger Sub”), and Sonnet BioTherapeutics, Inc., a New Jersey corporation (“Sonnet”), have entered into an Agreement and Plan of Merger, as amended (the “Merger Agreement”), pursuant to which Merger Sub will merge with and into Sonnet, with Sonnet surviving the merger as a wholly-owned subsidiary of the combined company. These transactions are referred to herein collectively as the “merger.” Following the merger, Chanticleer will be renamed “Sonnet BioTherapeutics Holdings, Inc.” and is sometimes referred to herein as the “combined company.” The shareholders of Sonnet will become the majority owners of Chanticleer’s outstanding common stock upon the closing of the merger. Additionally, as part of this transaction, Chanticleer will spin-off (the “Disposition”) its current restaurant operations, including all assets and liabilities, into a newly created entity (the “Spin-Off Entity”), the equity of which will be distributed out to the stockholders of Chanticleer as of the record date for the Disposition.   Pursuant to the Merger Agreement, each share of common stock of Sonnet, no par value per share (the “Sonnet Common Stock”) (other than Cancelled Shares (as defined in the Merger Agreement) and Dissenting Shares (as defined in the Merger Agreement)), issued and outstanding immediately prior to the effective time of the merger (the “Effective Time”) shall be automatically converted into the right to receive an amount of shares of common stock, par value $0.0001 per share, of Chanticleer (“Chanticleer Common Stock”) equal to the Common Stock Exchange Ratio (as defined in the Mer

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Chanticleer Holdings makes a similar move, sign up!

Other recent filings from the company include the following:

Chanticleer Holdings's Chief Medical Officer just picked up 21,314 shares - July 2, 2020
Chanticleer Holdings's Chief Technical Officer just picked up 73,613 shares - July 2, 2020
Chanticleer Holdings's Chief Scientific Officer just picked up 78,214 shares - July 2, 2020
Chanticleer Holdings's Chief Financial Officer just picked up 78,214 shares - July 2, 2020
Chanticleer Holdings director just picked up 8,005 shares - July 2, 2020

Auto Refresh

Feedback